Abstract

Previous studies have evaluated the risk factors for relapse of antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis (AAV) and the biomarkers of AAV for predicting relapse. However, little is known about the association between the presence of sinusitis and relapse and changes in the ANCA levels in AAV. This single-center, retrospective cohort study included 104 consecutive patients who were newly diagnosed with myeloperoxidase (MPO)-ANCA-positive microscopic polyangiitis (MPA) between 2006 and 2018 and were treated at the Aichi Medical University Hospital in Japan. The relationships between sinusitis and relapse of vasculitis and elevated MPO-ANCA levels were assessed using multivariate Cox proportional hazards models that were adjusted for clinically relevant factors. During the entire follow-up period (median, 24 months; interquartile range, 7–54 months), 93 (89.4%) patients achieved remission. After achieving remission, 38 (40.9%) patients experienced at least one relapse (13 [65.0%] in the sinusitis group; 25 [34.3%] in the non-sinusitis group). Sinusitis was identified as a significant predictor of relapse (adjusted hazard ratio: 2.41, 95% confidence interval [CI]: 1.19–4.88; P = 0.015). Furthermore, sinusitis was more likely to be associated with elevated MPO-ANCA levels (adjusted hazard ratio: 2.59, 95% CI: 1.14–5.92; P = 0.024). In conclusion, sinusitis was associated with a higher risk of relapse and elevated MPO-ANCA levels in MPA patients, suggesting that careful management may be required to reduce the risk of relapse in patients with sinusitis. Further studies are needed to elucidate the optimal treatment strategy for these patients.

Highlights

  • Antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis (AAV) is a disease characterized by small vessel inflammation and the presence of circulating ANCA

  • We aimed to evaluate the relationship between sinusitis, the relapse thereof, and the increased myeloperoxidase (MPO)-ANCA levels in microscopic polyangiitis (MPA) patients in Japan

  • The results were inconsistent in each cohort: In one community-based American cohort of 347 patients with newly diagnosed AAV, upper respiratory tract disease was identified as a significant risk factor for relapse in AAV (HR: 1.58, 95% confidence interval (CI): 1.00–2.48; P = 0.048)

Read more

Summary

Introduction

Antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis (AAV) is a disease characterized by small vessel inflammation and the presence of circulating ANCA. It includes granulomatosis with polyangiitis (GPA), microscopic polyangiitis (MPA), and eosinophilic. Relapse of ANCA-associated vasculitis granulomatosis with polyangiitis (EGPA) [1]. The accumulated clinical evidence on immunosuppressive treatment as an induction therapy for AAV has shown that remission and reduction of fatal organ damage are possible [2,3,4,5]. Frequent relapses may occur in up to 50% of the patients [2,3,4,5]. It is important to identify modifiable risk factors for relapse and distinguish a biomarker that reliably predicts relapse, and this remains a research goal

Objectives
Results
Conclusion
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call